SSR 103800
Alternative Names: SSR 103800A; SSR103800Latest Information Update: 16 Jul 2016
At a glance
- Originator sanofi-aventis
- Developer Sanofi
- Class Antipsychotics
- Mechanism of Action Glycine reuptake inhibitors; Glycine transporter 1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Schizophrenia
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-I development in Schizophrenia in France (PO)
- 03 Sep 2008 Pharmacodynamics data from preclinical trials in Schizophrenia presented at the 21st Annual Congress of the European College of Neuropsychopharmacology (ECNP-2008)
- 17 Oct 2007 Pharmacodynamics data from a preclinical trial in an animal model of Schizophrenia presented at the 20th Annual Congress of the European College of Neuropsychopharmacology (ECNP-2007)